NANOSONICS LIMITED — Director's Dealing 2010

Jun 7, 2010

==> picture [190 x 54] intentionally omitted <==

8[th] June 2010

Company Announcements Office Australian Securities Exchange

Changes in Director’s Interests

Nanosonics Limited (ASX:NAN) advises that the interests in the Company of two directors, Mr Maurie Stang and Dr David Fisher, have changed arising from the in-specie distribution of Nanosonics shares to investors in certain investment funds.

Appended below is the Company’s Appendix 3Y, Notice of Change in Director’s Interest, applicable in each instance.

Chris Grundy Company Secretary & CFO

For more information please contact Chris Grundy, Chief Financial Officer, on 61-2-8063 1600.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries. For more information about Nanosonics please visit www.nanosonics.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity: Nanosonics Limited ABN: 11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maurie Stang
Date of last notice	21stJanuary 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	In-specie distribution of invested funds, comprising 116,368 shares in Nanosonics Limited, to Novapharm Research (Australia) Pty Ltd and Epitek Corporation Pty Ltd
Date of change	2ndJune 2010
No. of securities held prior to change	Direct: 28,307,756 ordinary shares
Class	Fully paid quoted ordinary shares (ASX code NAN)
Number acquired	116,368 ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Value estimated to be $60,500
No. of securities held after change	Direct: 28,307,756 ordinary shares Indirect: 116,368 ordinary shares

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Nature of change In-specie distribution of invested funds, comprising Example: on-market trade, off-market trade, exercise 116,368 shares in Nanosonics Limited. of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
**Date of change **
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity: Nanosonics Limited ABN: 11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David Fisher
Date of last notice	21stJanuary 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	In-specie distribution of invested funds, comprising 135 shares in Nanosonics Limited, to Brandon Capital Management Pty Limited.
Date of change	7thJune 2010
No. of securities held prior to change	(a) by Brandon Capital Management Pty Limited: 852,281 ordinary shares. (b) by K6 Pty Limited: 101,235 ordinary shares.
Class	Fully paid quoted ordinary shares (ASX code NAN)
Number acquired	135 ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Value estimated to be $70

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	(a) by Brandon Capital Management Pty Limited: 852,416 ordinary shares. (b) by K6 Pty Limited: 101,235 ordinary shares.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	In-specie distribution of invested funds, comprising 135 shares in Nanosonics Limited

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
**Date of change **
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002